P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

• Hui Liu,
• Linghui Xia,
• Jianyu Weng,
• Fengkui Zhang,
• Chuan He,
• Sujun Gao,
• Jinsong Jia,
• Alice Chang,
• Wenjin LI,
• Sasha Sreckovic,
• Dayu Shi,
• Zilu Zhang,
• Rong Fu

Affiliations

Hui Liu

1 Tianjin Medical University General Hospital, Tianjin, China

Linghui Xia

2 Wuhan Union Hospital, Wuhan, China

Jianyu Weng

3 Guangdong Provincial People’s Hospital, Guangdong, China

Fengkui Zhang

4 Institute of Hematology and Blood Diseases Hospital, Tianjin, China

Chuan He

5 West China Hospital, Chengdu, China

Sujun Gao

6 The First Hospital of Jilin University, Department of Hematology, Changchun, China

Jinsong Jia

7 Peking University People’s Hospital, Beijing, China

Alice Chang

8 Genentech Inc., San Fransisco, United States

Wenjin LI

9 Roche Product Development, Shanghai, China

Sasha Sreckovic

8 Genentech Inc., San Fransisco, United States

Dayu Shi

9 Roche Product Development, Shanghai, China

Zilu Zhang

9 Roche Product Development, Shanghai, China

Rong Fu

1 Tianjin Medical University General Hospital, Tianjin, China